Klotho Therapeutics
San Diego
About Klotho Therapeutics
KLOTHO Therapeutics (KTI) is a biotechnology company developing patent-pending Klotho proteins with great potential to redefine society’s experience with aging. Klotho, a naturally occurring human protein discovered in 1997, promises to delay major diseases of aging – kidney failure, Alzheimer’s, osteoporosis, cancer, hypertension and diabetes, according to published studies. For example, National Institutes of Health report Klotho-deficient animals live 25% shorter and look older while animals overexpressing Klotho live 20-30% longer. The company’s first focus is on kidney failure, one of the major causes of death in the U.S. that affects up to 30 million people per year, 600,000 of whom are currently on dialysis. There is no successful long-term therapy today. KTI has filed patents on modified Klotho proteins covering its expansive potential indications.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Total funding: $10.0M
- Funding stage: Early Stage Venture
- Last round: Series A (Nov 2017)
- Website: klotho.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Health Care
Social Profiles
Canonical: https://fsome.com/organization/klotho-therapeutics-14104 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.